SCHEMBL15419583

SCHEMBL15419583

CC1C2CC3CC(CC1(C(=O)O)C3)C2NC(=O)CN1CCCN(c2ccccc2)S1(O)O

nearest known ligand 0.55

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 20/20 0.55
KCNH2 Q12809 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15419587 0.92 HSD11B1 (0.66) HSD11B1KCNH2
SCHEMBL15419653 0.84 HSD11B1 (0.57) HSD11B1KCNH2
SCHEMBL15419813 0.83 HSD11B1 (0.71) HSD11B1
SCHEMBL15420077 0.82 HSD11B1 (0.64) HSD11B1
SCHEMBL15419992 0.80 HSD11B1 (0.67) HSD11B1KCNH2
SCHEMBL15419777 0.80 HSD11B1 (0.83) HSD11B1KCNH2
SCHEMBL15419846 0.80 HSD11B1 (0.80) HSD11B1
SCHEMBL15419504 0.76 HSD11B1 (0.60) HSD11B1KCNH2
SCHEMBL15420079 0.74 HSD11B1 (0.74) HSD11B1KCNH2
SCHEMBL15419815 0.74 HSD11B1 (0.86) HSD11B1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2740723-B1 SULPHAMIDE DERIVATIVE HAVING AN ADAMANTYL GROUP AND A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF KOREA RES INST CHEMICAL TECH (KR) 2017-05-10 EP claimed
US-9073906-B2 Sulfamide derivative having an adamantyl group and its pharmaceutically acceptable salt KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2015-07-07 US claimed
EP-2740723-A2 SULPHAMIDE DERIVATIVE HAVING AN ADAMANTYL GROUP AND A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Korea Research Institute of Chemical Technology (KR) 2014-06-11 EP claimed
US-20140024636-A1 SULFAMIDE DERIVATIVE HAVING AN ADAMANTYL GROUP AND ITS PHARMACEUTICALLY ACCEPTABLE SALT KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2014-01-23 US claimed
US-20240108632-A1 PHARMACEUTICAL COMPOSITION FOR ADMINISTRATION AS OPHTHALMIC DROP TO PATIENT REQUIRING OPTIC NERVE PROTECTION PINOTBIO, INC. (KR) 2024-04-04 US disclosed
EP-2740723-B1 SULPHAMIDE DERIVATIVE HAVING AN ADAMANTYL GROUP AND A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF KOREA RES INST CHEMICAL TECH (KR) 2017-05-10 EP disclosed
US-9073906-B2 Sulfamide derivative having an adamantyl group and its pharmaceutically acceptable salt KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2015-07-07 US disclosed
EP-2740723-A2 SULPHAMIDE DERIVATIVE HAVING AN ADAMANTYL GROUP AND A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Korea Research Institute of Chemical Technology (KR) 2014-06-11 EP disclosed
US-20140024636-A1 SULFAMIDE DERIVATIVE HAVING AN ADAMANTYL GROUP AND ITS PHARMACEUTICALLY ACCEPTABLE SALT KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2014-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140024636-A1 SULFAMIDE DERIVATIVE HAVING AN ADAMANTYL GROUP AND ITS PHARMACEUTICALLY ACCEPTABLE SALT HSD11B1, HSD11B2, HSD3B1 HSD11B1 1/4885KCNH2 4365/4885
US-20240108632-A1 PHARMACEUTICAL COMPOSITION FOR ADMINISTRATION AS OPHTHALMIC DROP TO PATIENT REQUIRING OPTIC NERVE PROTECTION PMP22, PDE6C, DSC1 HSD11B1 154/4885KCNH2 3088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.